NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Genprex, Inc. GNPX
10 fiscal years on record · USD · FY2025 reported · SEC filings only
$-16.2M
Growth
—
Revenue, FY2025 · full 10-year series below
Revenue $M
Net income $M
FY2024 · Revenue 0.0 · Net income -21.1
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
ROE
FY2025 · ROE -338.7%
Each USD of equity lost 339 cents this year.
The 10-year record
10 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · | · | · |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | · | · | · | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | · | · | · | · | −0.42 | −0.51 | −0.66 | −0.90 | −0.29 | −0.38 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · |
| ROE % | −338.7 | −467.2 | −207.9 | −74.7 | −57.2 | −105.7 | −179.0 | −265.8 | −322.8 | −254.3 |
| Shares out B | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.04 | 0.02 | 0.02 | 0.01 | 0.01 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 40 reconciliationsAUDITED
Reconciled in 10 of 19 fiscal years. 36 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inTexas
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2016